Filing Flows › Collegium Pharmaceutical (COLL) › Q2 2026 › vs Q2 2025
Collegium Pharmaceutical (COLL) Q2 2026 vs Q2 2025 (year over year)
Collegium Pharmaceutical's revenue rose $11.9M (+6%) from $188M in Q2 2025 to $200M in Q2 2026. The biggest changes: Jornay PM +$13.4M (+41%); Azstarys +$12.9M (—); Nucynta IR −$12.1M (-46%).
Collegium Pharmaceutical, Q2 2026: revenue $200M (+6% year over year), operating margin 1.9%, net loss $15.1M, operating cash flow $71.3M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Free cash flow margin | 35.4% | 38.5% | -3.1 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Belbuca | $57.7M | $52.6M | $5.1M | +10% |
| Jornay PM | $46.1M | $32.6M | $13.4M | +41% |
| Xtampza ER | $45.0M | $52.6M | −$7.6M | -14% |
| Nucynta ER | $15.7M | $19.9M | −$4.2M | -21% |
| Nucynta IR | $14.4M | $26.5M | −$12.1M | -46% |
| Azstarys | $12.9M | $0 | $12.9M | — |
| Symproic | $3.0M | $3.7M | −$702K | -19% |
| Nucynta ER AG | $2.8M | $0 | $2.8M | — |
| Nucynta IR AG | $2.4M | $0 | $2.4M | — |
| Revenue | $200M | $188M | $11.9M | +6% |
| Net loss | $15.1M | −$12.0M | $27.0M | — |
| Costs & expenses | $215M | $188M | $26.9M | +14% |
| Operating costs | $196M | $153M | $43.3M | +28% |
| Interest & other, net | $17.2M | $18.1M | −$850K | -5% |
| Income tax | $1.5M | $5.0M | −$3.5M | -70% |
| Cost of revenue | $89.6M | $79.6M | $10.0M | +13% |
| Operating expenses | $107M | $73.3M | $33.3M | +45% |
| Operating cash sources | $86.4M | $60.5M | $25.9M | +43% |
| Depreciation & amortization | $64.8M | $56.6M | $8.2M | +14% |
| Share-based compensation | $14.5M | $10.8M | $3.7M | +34% |
| Working capital & other | $7.1M | −$7.0M | $14.1M | — |
| Net loss absorbed | $15.1M | −$12.0M | $27.0M | — |
| Operating cash flow | $71.3M | $72.4M | −$1.1M | -2% |
| Free cash flow (OCF − capex) | $70.8M | $72.4M | −$1.5M | -2% |
| Capital expenditures | $496K | $65K | $431K | +663% |
Questions
How much did Collegium Pharmaceutical's revenue grow year over year in Q2 2026?
Collegium Pharmaceutical's revenue rose $11.9M (+6%) from $188M in Q2 2025 to $200M in Q2 2026.
What drove Collegium Pharmaceutical's revenue change in Q2 2026?
Jornay PM +$13.4M (+41%); Azstarys +$12.9M (—); Nucynta IR −$12.1M (-46%).